Hanka L J
Cancer Treat Rep. 1979 Jun;63(6):1009-11.
A number of recent investigations have documented that, in several cancers, the malignant cells are no longer capable of synthesizing a specific amino acid, while the normal cells continue such biosynthesis at a normal rate. Enzymes degrading amino acids have demonstrated therapeutic value against such cancers. Significant progress was made recently in technology related to enzyme preparations. These are highly specific, have long half-lives, and can be chemically modified to eliminate their immunogenicity to man or animals. A practical in vitro system for detection of antimetabolites of different amino acids in natural materials was developed. It appears reasonable to expect that, in a specific malignancy, after the available pools of such deficient amino acids are exhausted by administration of the depleting enzyme, an additional, perhaps synergistic, effect could be obtained by utilizing an analog of such an amino acid. A brief review of the pertinent existing information will be presented in this communication.
最近的一些研究表明,在几种癌症中,恶性细胞不再能够合成特定的氨基酸,而正常细胞则以正常速率继续这种生物合成。降解氨基酸的酶已显示出对这类癌症的治疗价值。最近在与酶制剂相关的技术方面取得了重大进展。这些酶具有高度特异性,半衰期长,并且可以进行化学修饰以消除其对人或动物的免疫原性。开发了一种实用的体外系统,用于检测天然材料中不同氨基酸的抗代谢物。可以合理预期,在特定的恶性肿瘤中,在通过施用消耗酶耗尽此类缺乏氨基酸的可用库之后,通过使用此类氨基酸的类似物可能会获得额外的、也许是协同的效果。本通讯将简要回顾相关的现有信息。